Announcement on Convening the 2025 Semi-annual Performance Briefing
The abstract is for reference only. Please refer to the full text of the announcement on the very day.
Link of Full Text for Reference:
Announcement on Convening the 2025 Semi-annual Performance Briefing
Filed with SSE · · 2 pages · Chinese
Release
Earlier from Guobang Pharma
- Indicative Announcement on Expiration of the Lock-up Period of Phase I Employee Stock Ownership Plan
- 2025 Semi-annual Report
- Announcement on the Wholly-owned Subsidiary's Participation in the Establishment of the Equity Investment Fund and Completion of the Private Equity Fund Filing
- Announcement on Wholly-owned Subsidiary's Product Tulathromycin Passing European Union GMP Certification
- Announcement on Progress of Wholly-owned Subsidiary Participating in the Establishment of Equity Investment Fund
Later from Guobang Pharma
- Indicative Announcement on Proposed Share Transfer via Agreement by Company Shareholder to Introduce Strategic Investor and Related Change in Interests
- Announcement on Completion of Share Transfer of Ownership by Company Shareholders under Shareholder Agreement
- Notice on Convening the 1st Extraordinary General Meeting in 2025
- Announcement on Completing Term Change of Board of Directors and Appointing Senior Management Members and Securities Affairs Representative
- Announcement on Convening the Q3 2025 Performance Briefing
Follow Guobang Pharma into a list and get an email when it puts out news.
Follow Guobang Pharma